[
  {
    "nct_id": "NCT04526899",
    "title": "Study of Targeted Therapy in Advanced Solid Tumors with KRAS G12C Mutations",
    "condition": "Non-Small Cell Lung Cancer",
    "biomarkers": ["KRAS G12C"],
    "phase": "Phase 2",
    "status": "Recruiting",
    "line_of_therapy": "2nd line",
    "primary_endpoint": "Objective response rate",
    "secondary_endpoints": ["Progression-free survival", "Overall survival", "Duration of response"],
    "estimated_enrollment": 120,
    "intervention": "MRTX849 (Adagrasib)",
    "eligibility_criteria": {
      "age_range": {"min": 18, "max": null},
      "ecog_status": [0, 1],
      "required_biomarkers": ["KRAS G12C"],
      "prior_therapies": ["Platinum-based chemotherapy", "PD-1/PD-L1 inhibitor"]
    },
    "locations": [
      {"name": "Memorial Sloan Kettering Cancer Center", "city": "New York", "state": "NY", "lat": 40.764, "lon": -73.955},
      {"name": "Dana-Farber Cancer Institute", "city": "Boston", "state": "MA", "lat": 42.337, "lon": -71.100}
    ],
    "contact": {
      "phone": "646-888-4205",
      "email": "clinicaltrials@mskcc.org"
    }
  },
  {
    "nct_id": "NCT04875650",
    "title": "PARP Inhibitor Maintenance Therapy in BRCA-mutated Ovarian Cancer",
    "condition": "Ovarian Cancer",
    "biomarkers": ["BRCA1", "BRCA2"],
    "phase": "Phase 3",
    "status": "Active, not recruiting",
    "line_of_therapy": "1st line",
    "primary_endpoint": "Progression-free survival",
    "secondary_endpoints": ["Overall survival", "Quality of life", "Safety"],
    "estimated_enrollment": 300,
    "intervention": "Olaparib vs Placebo",
    "eligibility_criteria": {
      "age_range": {"min": 18, "max": null},
      "ecog_status": [0, 1, 2],
      "required_biomarkers": ["BRCA1", "BRCA2"],
      "prior_therapies": ["Platinum-based chemotherapy with complete or partial response"]
    },
    "locations": [
      {"name": "Stanford Cancer Institute", "city": "Stanford", "state": "CA", "lat": 37.434, "lon": -122.175},
      {"name": "MD Anderson Cancer Center", "city": "Houston", "state": "TX", "lat": 29.707, "lon": -95.397}
    ],
    "contact": {
      "phone": "650-498-7061",
      "email": "cancer-trials@stanford.edu"
    }
  },
  {
    "nct_id": "NCT05123456",
    "title": "HER2-targeted ADC in HER2-positive Breast Cancer",
    "condition": "Breast Cancer",
    "biomarkers": ["HER2 overexpression"],
    "phase": "Phase 1/2",
    "status": "Recruiting",
    "line_of_therapy": "3rd line",
    "primary_endpoint": "Maximum tolerated dose and recommended phase 2 dose",
    "secondary_endpoints": ["Objective response rate", "Safety", "Pharmacokinetics"],
    "estimated_enrollment": 80,
    "intervention": "T-DXd (Trastuzumab deruxtecan)",
    "eligibility_criteria": {
      "age_range": {"min": 18, "max": null},
      "ecog_status": [0, 1],
      "required_biomarkers": ["HER2 3+ by IHC or HER2 amplified by ISH"],
      "prior_therapies": ["Prior trastuzumab", "Prior pertuzumab", "Prior T-DM1"]
    },
    "locations": [
      {"name": "UCLA Jonsson Comprehensive Cancer Center", "city": "Los Angeles", "state": "CA", "lat": 34.069, "lon": -118.446},
      {"name": "Johns Hopkins Sidney Kimmel Cancer Center", "city": "Baltimore", "state": "MD", "lat": 39.295, "lon": -76.591}
    ],
    "contact": {
      "phone": "310-829-5471",
      "email": "jccc@mednet.ucla.edu"
    }
  },
  {
    "nct_id": "NCT04789012",
    "title": "CAR-T Cell Therapy in Relapsed/Refractory B-cell Lymphoma",
    "condition": "Diffuse Large B-Cell Lymphoma",
    "biomarkers": ["CD19 expression"],
    "phase": "Phase 2",
    "status": "Recruiting",
    "line_of_therapy": "3rd line",
    "primary_endpoint": "Complete response rate at 3 months",
    "secondary_endpoints": ["Overall response rate", "Duration of response", "Overall survival"],
    "estimated_enrollment": 100,
    "intervention": "Axicabtagene ciloleucel (Yescarta)",
    "eligibility_criteria": {
      "age_range": {"min": 18, "max": null},
      "ecog_status": [0, 1, 2],
      "required_biomarkers": ["CD19 positive"],
      "prior_therapies": ["At least 2 prior systemic therapies", "Relapsed/refractory disease"]
    },
    "locations": [
      {"name": "Fred Hutchinson Cancer Center", "city": "Seattle", "state": "WA", "lat": 47.623, "lon": -122.336},
      {"name": "City of Hope National Medical Center", "city": "Duarte", "state": "CA", "lat": 34.138, "lon": -117.976}
    ],
    "contact": {
      "phone": "206-667-2537",
      "email": "clinical@fredhutch.org"
    }
  },
  {
    "nct_id": "NCT05001234",
    "title": "Immunotherapy Combination in Microsatellite Instable Colorectal Cancer",
    "condition": "Colorectal Cancer",
    "biomarkers": ["MSI-H", "dMMR"],
    "phase": "Phase 3",
    "status": "Recruiting",
    "line_of_therapy": "1st line",
    "primary_endpoint": "Progression-free survival",
    "secondary_endpoints": ["Overall survival", "Objective response rate", "Quality of life"],
    "estimated_enrollment": 400,
    "intervention": "Pembrolizumab + Chemotherapy vs Chemotherapy alone",
    "eligibility_criteria": {
      "age_range": {"min": 18, "max": null},
      "ecog_status": [0, 1],
      "required_biomarkers": ["MSI-H or dMMR"],
      "prior_therapies": ["No prior systemic therapy for metastatic disease"]
    },
    "locations": [
      {"name": "Mayo Clinic", "city": "Rochester", "state": "MN", "lat": 44.022, "lon": -92.467},
      {"name": "Vanderbilt-Ingram Cancer Center", "city": "Nashville", "state": "TN", "lat": 36.143, "lon": -86.802}
    ],
    "contact": {
      "phone": "507-538-7623",
      "email": "mayoclinictrials@mayo.edu"
    }
  },
  {
    "nct_id": "NCT04567890",
    "title": "Precision Medicine Study in Advanced Pancreatic Cancer",
    "condition": "Pancreatic Cancer",
    "biomarkers": ["BRCA1", "BRCA2", "PALB2", "ATM"],
    "phase": "Phase 2",
    "status": "Recruiting",
    "line_of_therapy": "2nd line",
    "primary_endpoint": "Objective response rate",
    "secondary_endpoints": ["Progression-free survival", "Overall survival", "Safety"],
    "estimated_enrollment": 150,
    "intervention": "Olaparib in patients with homologous recombination deficiency",
    "eligibility_criteria": {
      "age_range": {"min": 18, "max": null},
      "ecog_status": [0, 1],
      "required_biomarkers": ["Germline or somatic BRCA1/2, PALB2, or ATM mutations"],
      "prior_therapies": ["One prior line of chemotherapy"]
    },
    "locations": [
      {"name": "University of Pennsylvania", "city": "Philadelphia", "state": "PA", "lat": 39.949, "lon": -75.193},
      {"name": "Northwestern Medicine", "city": "Chicago", "state": "IL", "lat": 41.895, "lon": -87.622}
    ],
    "contact": {
      "phone": "215-662-7910",
      "email": "onc-trials@pennmedicine.upenn.edu"
    }
  }
]